These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
245 related articles for article (PubMed ID: 23995614)
1. Knobs-into-holes antibody production in mammalian cell lines reveals that asymmetric afucosylation is sufficient for full antibody-dependent cellular cytotoxicity. Shatz W; Chung S; Li B; Marshall B; Tejada M; Phung W; Sandoval W; Kelley RF; Scheer JM MAbs; 2013; 5(6):872-81. PubMed ID: 23995614 [TBL] [Abstract][Full Text] [Related]
2. Increased in vivo effector function of human IgG4 isotype antibodies through afucosylation. Gong Q; Hazen M; Marshall B; Crowell SR; Ou Q; Wong AW; Phung W; Vernes JM; Meng YG; Tejada M; Andersen D; Kelley RF MAbs; 2016; 8(6):1098-106. PubMed ID: 27216702 [TBL] [Abstract][Full Text] [Related]
3. A novel bicistronic gene design couples stable cell line selection with a fucose switch in a designer CHO host to produce native and afucosylated glycoform antibodies. Roy G; Martin T; Barnes A; Wang J; Jimenez RB; Rice M; Li L; Feng H; Zhang S; Chaerkady R; Wu H; Marelli M; Hatton D; Zhu J; Bowen MA MAbs; 2018 Apr; 10(3):416-430. PubMed ID: 29400603 [TBL] [Abstract][Full Text] [Related]
5. Antibody-receptor interactions mediate antibody-dependent cellular cytotoxicity. Sun Y; Izadi S; Callahan M; Deperalta G; Wecksler AT J Biol Chem; 2021 Jul; 297(1):100826. PubMed ID: 34044019 [TBL] [Abstract][Full Text] [Related]
6. XGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancer. Schanzer JM; Wartha K; Moessner E; Hosse RJ; Moser S; Croasdale R; Trochanowska H; Shao C; Wang P; Shi L; Weinzierl T; Rieder N; Bacac M; Ries CH; Kettenberger H; Schlothauer T; Friess T; Umana P; Klein C MAbs; 2016; 8(4):811-27. PubMed ID: 26984378 [TBL] [Abstract][Full Text] [Related]
7. Production of bispecific antibodies in "knobs-into-holes" using a cell-free expression system. Xu Y; Lee J; Tran C; Heibeck TH; Wang WD; Yang J; Stafford RL; Steiner AR; Sato AK; Hallam TJ; Yin G MAbs; 2015; 7(1):231-42. PubMed ID: 25427258 [TBL] [Abstract][Full Text] [Related]
8. FX knockout CHO hosts can express desired ratios of fucosylated or afucosylated antibodies with high titers and comparable product quality. Louie S; Haley B; Marshall B; Heidersbach A; Yim M; Brozynski M; Tang D; Lam C; Petryniak B; Shaw D; Shim J; Miller A; Lowe JB; Snedecor B; Misaghi S Biotechnol Bioeng; 2017 Mar; 114(3):632-644. PubMed ID: 27666939 [TBL] [Abstract][Full Text] [Related]
9. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose. Ferrara C; Grau S; Jäger C; Sondermann P; Brünker P; Waldhauer I; Hennig M; Ruf A; Rufer AC; Stihle M; Umaña P; Benz J Proc Natl Acad Sci U S A; 2011 Aug; 108(31):12669-74. PubMed ID: 21768335 [TBL] [Abstract][Full Text] [Related]
10. Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC. Repp R; Kellner C; Muskulus A; Staudinger M; Nodehi SM; Glorius P; Akramiene D; Dechant M; Fey GH; van Berkel PH; van de Winkel JG; Parren PW; Valerius T; Gramatzki M; Peipp M J Immunol Methods; 2011 Oct; 373(1-2):67-78. PubMed ID: 21855548 [TBL] [Abstract][Full Text] [Related]
11. Effector-attenuating Substitutions That Maintain Antibody Stability and Reduce Toxicity in Mice. Lo M; Kim HS; Tong RK; Bainbridge TW; Vernes JM; Zhang Y; Lin YL; Chung S; Dennis MS; Zuchero YJ; Watts RJ; Couch JA; Meng YG; Atwal JK; Brezski RJ; Spiess C; Ernst JA J Biol Chem; 2017 Mar; 292(9):3900-3908. PubMed ID: 28077575 [TBL] [Abstract][Full Text] [Related]
12. The "less-is-more" in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity. Pereira NA; Chan KF; Lin PC; Song Z MAbs; 2018 Jul; 10(5):693-711. PubMed ID: 29733746 [TBL] [Abstract][Full Text] [Related]
14. Antibody Afucosylation Augments CD16-Mediated Serial Killing and IFNγ Secretion by Human Natural Killer Cells. Karampatzakis A; Brož P; Rey C; Önfelt B; Cruz De Matos GDS; Rycroft D; Ambrose A; Davis DM Front Immunol; 2021; 12():641521. PubMed ID: 33796107 [TBL] [Abstract][Full Text] [Related]
15. Generation of FX Liu W; Padmashali R; Monzon OQ; Lundberg D; Jin S; Dwyer B; Lee YJ; Korde A; Park S; Pan C; Zhang B Biotechnol Prog; 2021 Jan; 37(1):e3061. PubMed ID: 32748555 [TBL] [Abstract][Full Text] [Related]
16. Assessment of the role of afucosylated glycoforms on the Kwiatkowski A; Co C; Kameoka S; Zhang A; Coughlin J; Cameron T; Chiao E; Bergelson S; Schmid Mason C MAbs; 2020; 12(1):1803645. PubMed ID: 32812835 [TBL] [Abstract][Full Text] [Related]
17. Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded bispecific antibody comprising of two single-chain antibodies linked to the antibody constant region. Natsume A; Wakitani M; Yamane-Ohnuki N; Shoji-Hosaka E; Niwa R; Uchida K; Satoh M; Shitara K J Biochem; 2006 Sep; 140(3):359-68. PubMed ID: 16861252 [TBL] [Abstract][Full Text] [Related]
18. Engineering host cell lines to reduce terminal sialylation of secreted antibodies. Naso MF; Tam SH; Scallon BJ; Raju TS MAbs; 2010; 2(5):519-27. PubMed ID: 20716959 [TBL] [Abstract][Full Text] [Related]
19. 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. Ridgway JB; Presta LG; Carter P Protein Eng; 1996 Jul; 9(7):617-21. PubMed ID: 8844834 [TBL] [Abstract][Full Text] [Related]
20. Structural differences between glycosylated, disulfide-linked heterodimeric Knob-into-Hole Fc fragment and its homodimeric Knob-Knob and Hole-Hole side products. Kuglstatter A; Stihle M; Neumann C; Müller C; Schaefer W; Klein C; Benz J; Protein Eng Des Sel; 2017 Sep; 30(9):649-656. PubMed ID: 28985438 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]